Association of osteopontin polymorphisms with nasopharyngeal carcinoma risk

Abstract No previous study has reported the association of osteopontin polymorphisms with nasopharyngeal carcinoma (NPC) risk. We aimed to investigate the association in a Chinese population. Four variants of osteopontin, rs11730582, rs1126772, rs9138, and rs4754 polymorphisms, were assessed in a case-control study which consists of 108 NPC patients and 210 health controls, by using polymerase chain reaction – restriction fragment length polymorphism method. Serum osteopontin levels were measured by enzyme-linked immunosorbent assay. The serum osteopontin levels were significantly higher in NPC patients than those in controls ( P < 0.01). Carriers of CC and CT genotype of rs11730582 presented lower serum osteopontin levels than those of TT genotype carriers ( P < 0.05). Genotypes CT and CT + CC of rs11730582 were associated with the risk of NPC (CT:OR = 0.57, 95%CI = 0.34–0.94; CC + CT:OR = 0.54, 95%CI = 0.34–0.87). Haplotype analysis revealed that haplotype T-A-A-C of rs11730582, rs1126772, rs9138, and rs4754 was associated with NPC risk (OR = 0.49, 95%CI = 0.27–0.86). Stratification analysis showed that genotypes CT and CT + CC of rs11730582 were associated with tumor stage and lymph node metastasis ( P < 0.05). No associations were found between rs1126772, rs9138, and rs4754 polymorphisms and NPC risk ( P > 0.05). The variant rs11730582 of osteopontin is associated with NPC risk. It potentially serves as a genetic marker of NPC predisposition.